POSSIBLE ASSOCIATION BETWEEN REYE SYNDROME AND MEDICATION

Forms and Documents

Document Name	Status

No forms / supporting documents in this ICR. Check IC Document Collections.

IC Document Collections

IC ID	Document Title	Status
110807	POSSIBLE ASSOCIATION BETWEEN REYE SYNDROME AND MEDICATION	Migrated

ICR Details

OMB Control No: 0920-0163	ICR Reference No: 198409-0920-003
Status: Historical Active	Previous ICR Reference No:
Agency/Subagency: HHS/CDC	Agency Tracking No:
Title: POSSIBLE ASSOCIATION BETWEEN REYE SYNDROME AND MEDICATION
Type of Information Collection: New collection (Request for a new OMB Control Number)	Common Form ICR:  No
Type of Review Request: Regular
OIRA Conclusion Action: Approved without change	Conclusion Date: 12/07/1984
	Date Received in OIRA: 09/10/1984
Terms of Clearance: THIS REQUEST FOR CLEARANCE IS APPROVED PROVIDING THE STUDY DESIGN AND ANALYTICAL PLAN ARE MODIFIED AS FOLLOWS: 1. PRIOR TO ANALYZING THE DATA, CDC SHALL DEVELOP A SEVERITY INDEX OF THE ANTECEDENT ILLNESSES, AND WELL DEFINED CRITERIA FOR DETER MINING THE ONSET OF REYES SYNDROME. BOTH THE INDEX AND CRITERIA SHALL BE REVIEWED BY THE INSTITUTE OF MEDICINE PRIOR TO APPLICATION OF THE STUDY. 2. THE STATISTICAL TESTS AND ESTIMATES WILL BE CALCULATED AT THE CONCLUSION OF THE TWO YEAR STUDY PERIOD ON ALL THE DATA IN ORDER TO INSURE THAT THE FINAL RESULTS WILL HAVE THE 90 PERCENT POWER OF DETECTING A RELATIVE RISK OF 4.0 AS PROPOSED BY CDC. CDC HAS NOT DEMONSTRATED THAT THE MIDPOINT ANALYSIS WILL HAVE THE DESIRED POWER, ANND THEREFORE, SUCH AN INTERIM ANALYSIS COULD SERIOUSLY LOWER THE LIKLIHOOD OF DETECTING A POSITIVE ASSOCIATION BETWEEN USE OF MEDICATION AND REYES SYNDROME AT THE FINAL DATA ANALYSIS STAGE THEREBY DIMINISHING THE PRACTICAL UTILITY OF THE STUDY. AN INTERIM ANALYSIS MAY BE CONDUCTED AFTER CDC HAS DEMONSTRATED THAT THE FINAL EXPECTED POWER REMAINS AT OR ABOVE 90 PERCENT. 3. WHERE THERE IS ANY RISK AT ALL OF DETERIORATION OF THE CASES CONDITION, THE INTERVIEW OF THE CARE PROVIDER MUST NOT BE DELAYED. 4. BY SEPTEMBER 1985, HHS/CDC SHALL SUBMIT A DETAILED DATA ANALYSIS PLAN TO THE INSTITUTE OF MEDICINE FOR REVIEW BY IOM.

	Inventory as of this Action	Requested	Previously Approved
Expiration Date	05/31/1986	05/31/1986
Responses	1,350	0	0
Time Burden (Hours)	1,581	0	0
Cost Burden (Dollars)	0	0	0

---

Abstract: THIS PROPOSED STUDY WILL EXAMINE THE POSSIBLE RELATIONSHIP BETWEEN REY SYNDROME AND SALICYLATES. THE INFORMATION DERVIED WILL BE USED FOR DECISIONS RELATED TO RECOMMENDATIONS AND WARNINGS REGARDING THE USE OF MEDICATIONS FOR SAFELY TREATING CHILDHOOD ILLNESSES. PAREN OR GUARDIANS OF CASES AND CONTROLS WILL BE INTERVIEWED CONCERNING MEDICATIONS TAKEN, SYMPTOMS AND CONDITIONS DURING ILLNESS.

---

Authorizing Statute(s): None

Citations for New Statutory Requirements: None

---

Associated Rulemaking Information
RIN:	Stage of Rulemaking:	Federal Register Citation:	Date:

---

Federal Register Notices & Comments

Did the Agency receive public comments on this ICR? No

---

Number of Information Collection (IC) in this ICR: 1

IC Title	Form No.	Form Name
POSSIBLE ASSOCIATION BETWEEN REYE SYNDROME AND MEDICATION

---

ICR Summary of Burden

	Total Approved	Previously Approved	Change Due to New Statute	Change Due to Agency Discretion	Change Due to Adjustment in Estimate	Change Due to Potential Violation of the PRA
Annual Number of Responses	1,350	0	0	1,350	0	0
Annual Time Burden (Hours)	1,581	0	0	1,581	0	0
Annual Cost Burden (Dollars)	0	0	0	0	0	0

Burden increases because of Program Change due to Agency Discretion: Yes

Burden Increase Due to:

Burden decreases because of Program Change due to Agency Discretion: No

Burden Reduction Due to:

Short Statement:

---

Annual Cost to Federal Government: $0

Does this IC contain surveys, censuses, or employ statistical methods? No

Is the Supporting Statement intended to be a Privacy Impact Assessment required by the E-Government Act of 2002? No

Is this ICR related to the Affordable Care Act [Pub. L. 111-148 & 111-152]? Uncollected

Is this ICR related to the Dodd-Frank Wall Street Reform and Consumer Protection Act, [Pub. L. 111-203]? Uncollected

Is this ICR related to the American Recovery and Reinvestment Act of 2009 (ARRA)? Uncollected

Is this ICR related to the Pandemic Response? Uncollected

---

Common Form ICR:  No

---

On behalf of this Federal agency, I certify that the collection of information encompassed by this request complies with 5 CFR 1320.9 and the related provisions of 5 CFR 1320.8(b)(3).

The following is a summary of the topics, regarding the proposed collection of information, that the certification covers:

(a) It is necessary for the proper performance of agency functions;

(b) It avoids unnecessary duplication;

(c) It reduces burden on small entities;

(d) It uses plain, coherent, and unambiguous language that is understandable to respondents;

(e) Its implementation will be consistent and compatible with current reporting and recordkeeping practices;

(f) It indicates the retention periods for recordkeeping requirements;

(g) It informs respondents of the information called for under 5 CFR 1320.8 (b)(3) about:

(i) Why the information is being collected;

(ii) Use of information;

(iii) Burden estimate;

(iv) Nature of response (voluntary, required for a benefit, or mandatory);

(v) Nature and extent of confidentiality; and

(vi) Need to display currently valid OMB control number;

(h) It was developed by an office that has planned and allocated resources for the efficient and effective management and use of the information to be collected.

(i) It uses effective and efficient statistical survey methodology (if applicable); and

(j) It makes appropriate use of information technology.

If you are unable to certify compliance with any of these provisions, identify the item by leaving the box unchecked and explain the reason in the Supporting Statement.

Certification Date: 09/10/1984

---